Corneal neovascularization (CoNV) is both a sight-threatening condition in and of itself and a major risk factor associated with corneal graft failure. Here, we determine the effectiveness of an adeno-associated viral vector (AAV)-based gene therapy targeting both hematic and lymphatic neovascularization in a murine model of severe CoNV. We first assessed the profile of transgene expression mediated by intrastromal injection of AAV2/8[Y733F] via longitudinal visualization of an enhanced Green Fluorescent Protein (eGFP) transgene and found that this serotype mediates a temporary (∼18 day) transduction of the corneal epithelium and sustained (≥148 day) transduction within the stroma. Constitutively expressed sFlt1 or sFlt4 were prophylactically delivered via intrastromal injection of AAV2/8[Y733F] vector at various intervals prior to aggressive induction of CoNV in a murine model. The extent of CoNV induced was quantified by fluorescein angiography and immunohistochemistry 17 days after induction. AAV2/8[Y733F]-CMV-sFlt1 was highly effective in the prevention of hemangiogenesis (HA) induced at 3, 28, and 210 days after intrastromal injection, but ineffective in the prevention of lymphangiogenesis. Two variants of AAV2/8[Y733F]-CMV-sFlt4 were ineffective in the prevention of angiogenesis when delivered alone, but combined delivery of AAV2/8[Y733F]-CMV-sFlt1 and AAV2/8[Y733F]-CMV-sFlt4 suggested a synergistic effect. Our results show that a single intrastromal injection of AAV2/8[Y733F]-CMV-sFlt1 is sufficient to protect against a robust stimulus for corneal HA over the long term. This technique could also be applied ex vivo to reduce the risk of failure in cases of “high-risk” corneal transplantation.
AmbatiBK, NozakiM, SinghN, et al.Corneal avascularity is due to soluble VEGF receptor-1. Nature, 2006; 443(7114):993–997; doi: 10.1038/nature05249
5.
SinghN, TiemM, WatkinsR, et al.Soluble vascular endothelial growth factor receptor 3 is essential for corneal alymphaticity. Blood, 2013; 121(20):4242–4249; doi: 10.1182/blood-2012-08-453043
6.
ReginaM, ZimmermanR, MalikG, et al.Lymphangiogenesis concurrent with haemangiogenesis in the human cornea. Clin Exp Ophthalmol, 2007; 35(6):541–544; doi: 10.1111/j.1442-9071.2007.01549.x
MaDH-K, ChenJ-K, ZhangF, et al.Regulation of corneal angiogenesis in limbal stem cell deficiency. Prog Retin Eye Res, 2006; 25(6):563–590.
9.
NakaoS, KuwanoT, Tsutsumi-MiyaharaC, et al.Infiltration of COX-2-expressing macrophages is a prerequisite for IL-1 beta-induced neovascularization and tumor growth. J Clin Invest, 2005; 115(11):2979–2991; doi: 10.1172/JCI23298
10.
PhilippW, SpeicherL, HumpelC. Expression of vascular endothelial growth factor and its receptors in inflamed and vascularized human corneas. Invest Ophthalmol Vis Sci, 2000; 41(9):2514–2522.
11.
WilsonSE. Corneal myofibroblast biology and pathobiology: Generation, persistence, and transparency. Exp Eye Res, 2012; 99(1):78–88; doi: 10.1016/j.exer.2012.03.018
12.
BorderieVM, BoëlleP-Y, TouzeauO, et al.Predicted long-term outcome of corneal transplantation. Ophthalmology, 2009; 116(12):2354–2360.
13.
CursiefenC. Immune privilege and angiogenic privilege of the cornea. Chem Immunol Allergy, 2007; 92:50–57; doi: 10.1159/000099253
14.
NiederkornJY. Corneal transplantation and immune privilege. Int Rev Immunol, 2013; 32(1):57–67; doi: 10.3109/08830185.2012.737877
15.
MaguireMG, StarkWJ, GottschJD, et al.Risk factors for corneal graft failure and rejection in the collaborative corneal transplantation studies. Collaborative Corneal Transplantation Studies Research Group. Ophthalmology, 1994; 101(9):1536–1547.
16.
WilliamsKA, LoweM, BartlettC, et al.; All Contributors. Risk factors for human corneal graft failure within the Australian corneal graft registry. Transplantation, 2008; 86(12):1720–1724; doi: 10.1097/TP.0b013e3181903b0a
17.
RahmanI, CarleyF, HillarbyC, et al.Penetrating keratoplasty: Indications, outcomes and complications. Eye (Lond), 2009; 23(6):1288–1294; doi: 10.1038/eye.2008.305
18.
BachmannB, TaylorRS, CursiefenC. Corneal neovascularization as a risk factor for graft failure and rejection after keratoplasty: An evidence-based meta-analysis. Ophthalmology, 2010; 117(7):1300–1305.e7; doi: 10.1016/j.ophtha.2010.01.039
19.
DanaM, StreileinJ. Loss and restoration of immune privilege in eyes with corneal neovascularization. Invest Ophthalmol Vis Sci, 1996; 37(12):2485–2494.
20.
NiederkornJY. High-risk corneal allografts and why they lose their immune privilege. Curr Opin Allergy Clin Immunol, 2010; 10(5):493–497; doi: 10.1097/ACI.0b013e32833dfa11
21.
DietrichT, BockF, YuenD, et al.Cutting edge: Lymphatic vessels, not blood vessels, primarily mediate immune rejections after transplantation. J Immunol, 2010; 184(2):535–539; doi: 10.4049/jimmunol.0903180
22.
ZhengY, LinH, LingS. Clinicopathological correlation analysis of (lymph) angiogenesis and corneal graft rejection. Mol Vis, 2011; 17:1694–1700.
23.
AlbuquerqueRJC, HayashiT, ChoWG, et al.Alternatively spliced vascular endothelial growth factor receptor-2 is an essential endogenous inhibitor of lymphatic vessel growth. Nat Med, 2009; 15(9):1023–1030; doi: 10.1038/nm.2018
24.
PillaiCT, DuaHS, HossainP. Fine needle diathermy occlusion of corneal vessels. Invest Ophthalmol Vis Sci, 2000; 41(8):2148–2153.
25.
BrooksBJ, AmbatiBK, MarcusDM, et al.Photodynamic therapy for corneal neovascularisation and lipid degeneration. Br J Ophthalmol, 2004; 88(6):840.
26.
SchaubF, HouY, ZhangW, et al.Corneal crosslinking to regress pathologic corneal neovascularization before high-risk keratoplasty. Cornea, 2021; 40(2):147–155; doi: 10.1097/ICO.0000000000002406
27.
ChangJH, GargNK, LundeE, et al.Corneal neovascularization: An anti-VEGF therapy review. Surv Ophthalmol, 2012; 57(5):415–429; doi: 10.1016/j.survophthal.2012.01.007
28.
BachmannBO, BockF, WiegandSJ, et al.Promotion of graft survival by vascular endothelial growth factor a neutralization after high-risk corneal transplantation. Arch Ophthalmol, 2008; 126(1):71–77; doi: 10.1001/archopht.126.1.71
29.
PetsoglouC, BalagganKS, DartJKG, et al.Subconjunctival bevacizumab induces regression of corneal neovascularisation: A pilot randomised placebo-controlled double-masked trial. Br J Ophthalmol, 2013; 97(1):28–32; doi: 10.1136/bjophthalmol-2012-302137
30.
AurnhammerC, HaaseM, MuetherN, et al.Universal real-time PCR for the detection and quantification of adeno-associated virus serotype 2-derived inverted terminal repeat sequences. Hum Gene Ther Methods, 2012; 23(1):18–28; doi: 10.1089/HGTB.2011.034
SchindelinJ, Arganda-CarrerasI, FriseE, et al.Fiji: An open-source platform for biological-image analysis. Nat Methods, 2012; 9(7):676–682; doi: 10.1038/nmeth.2019
33.
BascheM, KampikD, KawasakiS, et al.Sustained and widespread gene delivery to the corneal epithelium via In Situ Transduction of limbal epithelial stem cells, using lentiviral and adeno-associated viral vectors. Hum Gene Ther, 2018; 29(10):1140–1152; doi: 10.1089/hum.2018.115
34.
NagyJA, VasileE, FengD, et al.Vascular permeability factor/vascular endothelial growth factor induces lymphangiogenesis as well as angiogenesis. J Exp Med, 2002; 196(11):1497–1506.
35.
CreweJM, ArmitageWJ. Integrity of epithelium and endothelium in organ-cultured human corneas. Invest Ophthalmol Vis Sci, 2001; 42(8):1757–1761.
36.
DohlmanTH, OmotoM, HuaJ, et al.VEGF-trap aflibercept significantly improves long-term graft survival in high-risk corneal transplantation. Transplantation, 2015; 99(4):678–686; doi: 10.1097/TP.0000000000000512
37.
HippertC, IbanesS, SerratriceN, et al.Corneal transduction by intra-stromal injection of AAV vectors in vivo in the mouse and ex vivo in human explants. PLoS One, 2012; 7(4):e35318; doi: 10.1371/journal.pone.0035318
38.
TsaiM-L, ChenS-L, ChouP-I, et al.Inducible adeno-associated virus vector-delivered transgene expression in corneal endothelium. Invest Ophthalmol Vis Sci, 2002; 43(3):751–757.
39.
GoaterJ, MüllerR, KolliasG, et al.Empirical advantages of adeno associated viral vectors in vivo gene therapy for arthritis - PubMed. J Rheumatol, 2000; 27(4):983–989.
40.
BockF, OnderkaJ, DietrichT, et al.Blockade of VEGFR3-signalling specifically inhibits lymphangiogenesis in inflammatory corneal neovascularisation. Graefe’s Archive for Clinical and Experimental Ophthalmology, 2008; doi: 10.1007/s00417-007-0683-5
41.
Emami-NaeiniP, DohlmanTH, OmotoM, et al.Soluble vascular endothelial growth factor receptor-3 suppresses allosensitization and promotes corneal allograft survival. Graefe’s Archive for Clinical and Experimental Ophthalmology, 2014; doi: 10.1007/s00417-014-2749-5
42.
ChoYK, UeharaH, YoungJR, et al.Vascular endothelial growth factor receptor 1 morpholino decreases angiogenesis in a murine corneal suture model. Invest Ophthalmol Vis Sci, 2012; 53(2):685–692; doi: 10.1167/iovs.11-8391
43.
StuartPM, PanF, PlambeckS, et al.FasL-Fas interactions regulate neovascularization in the cornea. Invest Ophthalmol Vis Sci, 2003; 44(1):93–98; doi: 10.1167/IOVS.02-0299
44.
SuzukiT, SanoY, KinoshitaS. Conjunctival inflammation induces Langerhans cell migration into the cornea. Curr Eye Res, 2000; 21(1):550–553; doi: 10.1076/0271-3683(200007)2111-ZFT550
45.
RegenfussB, OnderkaJ, BockF, et al.Genetic heterogeneity of lymphangiogenesis in different mouse strains. Am J Pathol, 2010; 177(1):501–510; doi: 10.2353/ajpath.2010.090794
46.
HalinC, ToblerNE, ViglB, et al.VEGF-A produced by chronically inflamed tissue induces lymphangiogenesis in draining lymph nodes. Blood, 2007; 110(9):3158–3167; doi: 10.1182/blood-2007-01-066811
47.
NakaoS, ZandiS, HataY, et al.Blood vessel endothelial VEGFR-2 delays lymphangiogenesis: An endogenous trapping mechanism links lymph- and angiogenesis. Blood, 2011; 117(3):1081–1090; doi: 10.1182/BLOOD-2010-02-267427
48.
CursiefenC, ChenL, BorgesLP, et al.VEGF-A stimulates lymphangiogenesis and hemangiogenesis in inflammatory neovascularization via macrophage recruitment. J Clin Invest, 2004; 113(7):1040–1050; doi: 10.1172/JCI20465
49.
OlssonA-K, DimbergA, KreugerJ, et al.VEGF receptor signalling - in control of vascular function. Nat Rev Mol Cell Biol, 2006; 7(5):359–371; doi: 10.1038/nrm1911
50.
SimonsM, GordonE, Claesson-WelshL. Mechanisms and regulation of endothelial VEGF receptor signalling. Nat Rev Mol Cell Biol, 2016; 17(10):611–625; doi: 10.1038/nrm.2016.87
51.
DomiganCK, ZiyadS, Luisa Iruela-ArispeM. Canonical and non-canonical VEGF pathways: New developments in biology and signal transduction. Arterioscler Thromb Vasc Biol, 2015; 35(1):30–39; doi: 10.1161/ATVBAHA.114.303215
OsakiT, SerranoJC, KammRD. cooperative effects of vascular angiogenesis and lymphangiogenesis. Regen Eng Transl Med, 2018; 4(3):120–132; doi: 10.1007/s40883-018-0054-2
54.
Planas-PazL, StrilićB, GoedeckeA, et al.Mechanoinduction of lymph vessel expansion. Embo J, 2012; 31(4):788–804; doi: 10.1038/EMBOJ.2011.456/SUPPL_FILE/EMBJ2011456.REVIEWER_COMMENTS.PDF
55.
TakahashiH, ShibuyaM. The vascular endothelial growth factor (VEGF)/VEGF receptor system and its role under physiological and pathological conditions. Clin Sci (Lond), 2005; 109(3):227–241; doi: 10.1042/cs20040370
56.
LeeS, JilanSM, NikolovaGV, et al.Processing of VEGF-A by matrix metalloproteinases regulates bioavailability and vascular patterning in tumors. J Cell Biol, 2005; 169(4):681–691; doi: 10.1083/JCB.200409115
57.
SuW, SunS, TianB, et al.Efficacious, safe, and stable inhibition of corneal neovascularization by AAV-vectored anti-VEGF therapeutics. Mol Ther Methods Clin Dev, 2021; 22:107–121; doi: 10.1016/J.OMTM.2021.06.007
58.
LaiCM, BrankovM, ZaknichT, et al.Inhibition of angiogenesis by adenovirus-mediated sFlt-1 expression in a rat model of corneal neovascularization. Hum Gene Ther, 2001; 12(10):1299–1310; doi: 10.1089/104303401750270959
59.
LaiYKY, ShenWY, BrankovM, et al.Potential long-term inhibition of ocular neovascularisation by recombinant adeno-associated virus-mediated secretion gene therapy. Gene Ther, 2002; 9(12):804–813; doi: 10.1038/sj.gt.3301695
60.
LaiL-J, XiaoX, WuJH. Inhibition of corneal neovascularization with endostatin delivered by adeno-associated viral (AAV) vector in a mouse corneal injury model. J Biomed Sci, 2007; 14(3):313–322; doi: 10.1007/s11373-007-9153-7
61.
ChengH-C, YehS-I, TsaoY-P, et al.Subconjunctival injection of recombinant AAV-angiostatin ameliorates alkali burn induced corneal angiogenesis. Mol Vis, 2007; 13:2344–2352.
62.
BalagganKS, BinleyK, EsapaM, et al.EIAV vector-mediated delivery of endostatin or angiostatin inhibits angiogenesis and vascular hyperpermeability in experimental CNV. Gene Ther, 2006; 13(15):1153–1165; doi: 10.1038/sj.gt.3302769
63.
MohanRR, ToveyJCK, SharmaA, et al.Targeted decorin gene therapy delivered with adeno-associated virus effectively retards corneal neovascularization in vivo. PLoS One, 2011; 6(10):e26432; doi: 10.1371/journal.pone.0026432
64.
HirschML, ConatserLM, SmithSM, et al.AAV vector-meditated expression of HLA-G reduces injury-induced corneal vascularization, immune cell infiltration, and fibrosis. Sci Rep, 2017; 7(1):17840; doi: 10.1038/S41598-017-18002-9
65.
LuY, TaiPWL, AiJ, et al.Transcriptome profiling of neovascularized corneas reveals miR-204 as a multi-target biotherapy deliverable by rAAVs. Mol Ther Nucleic Acids, 2018; 10:349–360; doi: 10.1016/J.OMTN.2017.12.019
66.
YuH, WuJ, LiH, et al.Inhibition of corneal neovascularization by recombinant adenovirus-mediated sFlk-1 expression. Biochem Biophys Res Commun, 2007; 361(4):946–952; doi: 10.1016/j.bbrc.2007.07.114
67.
VerderaHC, KurandaK, MingozziF. AAV vector immunogenicity in humans: A long journey to successful gene transfer. Mol Ther, 2020; 28(3):723–746; doi: 10.1016/J.YMTHE.2019.12.010
68.
LiQ, MillerR, HanP-Y, et al.Intraocular route of AAV2 vector administration defines humoral immune response and therapeutic potential. Mol Vis, 2008; 14:1760–1769.
69.
ClareAJ, LangerPM, WardA, et al.Characterisation of the ocular inflammatory response to AAV reveals divergence by sex and age. Mol Ther, 2025; 33(3):1246–1263; doi: 10.1016/J.YMTHE.2025.01.028
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
